Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

Canadian Cancer Trials Group IND. 198 - Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Over-Expressing Metastatic Breast Cancer - was closed to accrual on March 5, 2013. The trial will not proceed to the phase II portion of the study due to a lack of evidence of activity.

We would like to thank all of the centres, staff and patients who participated in this trial.